Affiliation:
1. University of Medicine and Pharmacy “Grigore T. Popa” Iași
Abstract
Abstract
Introduction. Although cardiovascular disease remains the leading cause of mortality regardless of gender, the female gender has remained an underrepresented population in studies in this field. Sustained initiatives by the European Society of Cardiology have brought to the fore the importance of studying gender differences regarding the safety profile of cardiovascular drugs in women. Common cardiovascular adverse drug reactions include atrioventricular conduction disorders.
Materials and methods. The present study followed the clinical and paraclinical features of female patients with a primary diagnosis of bradycardia in relation to bradycardic medication. We included a group of 359 female patients, divided according to the presence or absence of bradycardia medication into a study group (n=206) and a control group (n=153).
Results. Patients with associated bradycardic medication frequently required emergency admission (P < 0.001), with prolonged hospitalization (P < 0.001). The main atrioventricular conduction disorders identified were atrial fibrillation with slow ventricular response (P = 0.028), sinus bradycardia (P = 0.009) and sinus pauses (P = 0.009). Among comorbidities, heart failure (P<0.001) and chronic kidney disease (P<0.001), were common in the study group. Echocardiographic parameters of left ventricular (P=0.002) and biatrial (P<0.001) dilatation, as well as severe left ventricular systolic dysfunction (P=0.009), showed statistical significance in this group. The most used drugs were beta-blockers, amiodarone, and digoxin.
Conclusions. Our results indicate, as factors associated with medication-related bradyarrhythmias in female gender: heart failure with severe systolic dysfunction, renal dysfunction, atrial fibrillation, and left ventricular dilatation.
Reference34 articles.
1. 1. Roth GA, Mensah GA, Johnson CO, et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. J Am Coll Cardiol. 2020 Dec 22;76(25):2982-3021. doi: 10.1016/j.jacc.2020.11.010. Erratum in: J Am Coll Cardiol. 2021 Apr 20;77(15):1958-1959. PMID: 33309175; PMCID: PMC7755038.
2. 2. Tamargo J, Rosano G, Walther T, et al. Gender differences in the effects of cardiovascular drugs. Eur Heart J Cardiovasc Pharmacother. 2017 Jul 1;3(3):163-182. doi: 10.1093/ehjcvp/pvw042. PMID: 28329228.10.1093/ehjcvp/pvw042
3. 3. Bots SH, Groepenhoff F, Eikendal ALM, Tannenbaum C, Rochon PA, Regitz-Zagrosek V, Miller VM, Day D, Asselbergs FW, den Ruijter HM. Adverse Drug Reactions to Guideline-Recommended Heart Failure Drugs in Women: A Systematic Review of the Literature. JACC Heart Fail. 2019 Mar;7(3):258-266. doi: 10.1016/j. jchf.2019.01.009. PMID: 30819382.
4. 4. Rosano GM, Lewis B, Agewall S, et al. Gender differences in the effect of cardiovascular drugs: a position document of the Working Group on Pharmacology and Drug Therapy of the ESC. Eur Heart J. 2015 Oct 21;36(40):2677-80. doi: 10.1093/eurheartj/ehv161. Epub 2015 May 6. PMID: 25948737.10.1093/eurheartj/ehv161
5. 5. Stramba-Badiale M, Fox KM, Priori SG, et al. Cardiovascular diseases in women: a statement from the policy conference of the European Society of Cardiology. Eur Heart J. 2006 Apr;27(8):994-1005. doi: 10.1093/eurheartj/ehi819. Epub 2006 Mar 7. PMID: 16522654.10.1093/eurheartj/ehi819
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献